Karya Kwalba a cikin Kiba da Maganin Ciwon Suga: Babban Tasirin Tirzepatide.

Tirzepatide wani labari ne mai dual GIP/GLP-1 agonist mai karɓa wanda ya nuna babban alƙawari a cikin maganin cututtuka na rayuwa. Ta hanyar kwaikwayi ayyukan hormones na incretin guda biyu na halitta, yana haɓaka haɓakar insulin, yana danne matakan glucagon, kuma yana rage yawan cin abinci-yana taimakawa yadda yakamata don sarrafa glucose na jini da haɓaka asarar nauyi.

Dangane da alamun da aka yarda, a halin yanzu an ba da tirzepatide don sarrafa glucose na jini a cikin marasa lafiya da ke da nau'in ciwon sukari na 2 da kuma kula da nauyi na dogon lokaci a cikin mutane masu kiba ko kiba. Ingancin sa na asibiti yana da ƙarfi da goyan bayan karatu da yawa: jerin gwaji na SURPASS sun nuna cewa tirzepatide yana rage matakan HbA1c sosai a cikin allurai daban-daban kuma ya fi dacewa da jiyya na yanzu kamar semaglutide. A cikin sarrafa nauyi, gwaje-gwajen SURMOUNT sun ba da sakamako mai ban sha'awa-wasu marasa lafiya sun sami raguwar nauyin jiki kusan 20% a cikin shekara guda, sanya tirzepatide a matsayin ɗayan ingantattun magungunan rigakafin kiba a kasuwa.

Bayan ciwon sukari da kiba, yuwuwar aikace-aikacen tirzepatide suna haɓaka. Gwaje-gwajen asibiti da ke ci gaba da binciko amfani da shi wajen magance yanayi kamar steatohepatitis mara giya (NASH), cututtukan koda, da gazawar zuciya. Musamman ma, a cikin gwajin SUMMIT na 3, tirzepatide ya nuna raguwa mai yawa a cikin abubuwan da ke da alaƙa da gazawar zuciya a tsakanin marasa lafiya tare da raunin zuciya tare da juzu'in fitarwa (HFpEF) da kiba, yana ba da sabon bege ga manyan aikace-aikacen warkewa.